cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
(CAMPERR Trial)
Trial Summary
What is the purpose of this trial?
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid. These cancers were selected based on their prevalence and mortality to maximize impact on clinical care. Additionally, the ability of the whole-genome methylome enrichment platform to detect minimal residual disease after completion of cancer treatment and to detect relapse prior to clinical presentation will be evaluated in four cancer types (breast, colorectal, lung, prostate). These cancers were selected based on the existing clinical landscape and treatment availability.
Research Team
Brian Rini, MD
Principal Investigator
Vanderbilt-Ingram Cancer Center
Eligibility Criteria
Inclusion Criteria
Treatment Details
Interventions
- Genome-wide Methylome Enrichment Platform (Cancer Detection)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Alzheimer's Disease Expert Lab (ADEL), Inc.
Lead Sponsor
Adela, Inc.
Lead Sponsor
Adela, Inc
Lead Sponsor